Background & objectives: Vascular illnesses are on the rise in India, due to increase in lifestyle diseases and demographic transition, requiring intervention to save life, organ or limbs using vascular prosthesis. The aim of this study was to develop indigenous large diameter vascular graft for treatment of patients with vascular pathologies.
, the ideal characteristics of vascular prosthesis are indicated in Table I . The objective of this programme was the development of straight woven vascular prosthetic grafts of polyester in the size range of 10 to 25 mm internal diameter initially which should be comparable in safety and efficacy to the widely used commercially available vascular prostheses.
Material & Methods

Development & in vitro testing:
Designed and fabricated at South India Textile Research Association (SITRA), Coimbatore, the main testing and clinical work of woven grafts was carried out at Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), Thiruvananthapuram, Kerala, India. The prosthesis was essentially made of polyester polyethylene terephthalate (PET). The design and developmental process included yarn preparation, weaving of the tubular fabric, crimping and sterilization. The fabric was a seamless woven tube of 75 denier texturised polyester yarn which was suitably crimped (Fig. 1) to provide large diameter vascular graft with a porosity of 200±50 ml/min/cm 2 of normal saline at 120 mmHg. The physical characteristics of the yarn, in terms of the yarn count, yarn twist and tensile strength to weave the grafts were determined by SITRA. The chemical composition of the material was analysed by infrared spectroscopy using spectrophotometer (Shimadzu, Japan), and differential thermal analysis at the laboratory for technical evaluation of biomaterials at the biomedical Division of SCTIMST. Toxicity/ biocompatibility studies such as acute systemic toxicity, intracutaneous irritation, in vitro haemolysis and implantation in muscle were studied as per international standards 3 for the vascular graft material. Acute systemic toxicity was studied in mice using physiological saline and cotton seed oil extracts of the material. Intracutaneous irritation was done by injecting the extracts of material and control intradermally into rabbits under ketamine anaesthesia. Grading of erythema and oedema of material in experimental and control rabbits were recorded at 24, 48 and 72 h. In vitro haemolysis was carried out with material and extract of the material using centrifugation (REMI R-8C DX, India) with rabbit blood. The muscle implantation was carried out in nine albino rabbits. The implanted animals were sacrificed at the end of one, four and 12 wk, the tissue with the implanted materials were collected, sectioned using RM2255 microtome (Leica, biosystems, India) and subjected to histopathological analysis (Axio Imager Z1 microscope, Carl Zeiss). fasting and premedication, general anaesthesia was employed using thiopentone sodium (10 mg/kg) and muscle relaxants and maintained with endotracheal intubation and inhalation anaesthetic agents. Open cut down was employed to obtain central venous access through saphenous vein and arterial access through femoral artery. Continuous monitoring of heart rate, blood pressure, electrocardiogram (ECG) and arterial blood gases (ABG) at regular intervals formed the standard protocol. Left postero-lateral thoracotomy was performed and pleural cavity entered by excising 4 th or 5 th rib. Lung was gently retracted and mediastinal pleura over descending thoracic aorta incised and aorta dissected and looped. Dissection was continued as far as feasible towards suprahiatal aorta whenever long grafts had to be implanted. Heparin (1 mg/kg) was administered three minutes prior to clamping in some cases except where blood retrieval strategy was employed in which case 3 mg/kg was required 7 . Cardiotomy reservoir with suction device was utilized to retrieve shed blood during most procedures. After completion of arterial grafting (Fig. 3A) , protamine was administered and haemostasis achieved. Thoracotomy was closed without indwelling chest drainage tube. All animals except one could be extubated at the end of procedure and walked back to cage 4-6 h after completion of the procedure. They were given water and feeds from next day morning. Streptopenicillin injection was given for five days for infection prophylaxis. The surviving animals were followed up for three and six months as per protocol.
Grafts were explanted to study the healing characteristics, blood/tissue interactions and patency rates. Explantation was performed at three months or six months following graft insertion under general anaesthesia; 1 mg/kg heparin was administered to avoid misinterpretation of pre-or postmortem thrombus.
Phase I clinical trial:
(i) Design -Prospective randomized study was designed to prove non-inferiority of the test prosthesis with concurrent controls using commercially available prosthetic grafts. Objective patency assessment was made by non-invasive haemodynamic indices, duplex ultrasound and catheter angiography/CT angiography.
(ii) Parameters evaluated were (a) ease of preclotting; (b) pliability/conformability; (c) ease of suturing/suture retention; and (d) short-term patency at one year, long-term patency at five years and beyond.
(iii) Institutional Ethics committee (IEC) gave permission to use large diameter prosthesis of length less than 10 cm for a total of 10 patients during phase I trial as a matter of abundant caution. This restricted its use only for repair of abdominal aortic aneurysms (AAA) and coarctation of thoracic aorta (CoA). Special and detailed informed consent was obtained in every patient included in the study.
(iv) Methods -Between September 1998 and November 1999, 10 patients were included in phase I clinical trial using the test graft at SCTIMST, six of whom underwent repair for AAA and four for CoA (Table II) . AAA involved the infra-renal segment of aorta which was repaired through xipho-pubic midline laparotomy and transperitoneal approach to the aorta. Standard inclusion graft technique was performed using appropriate (14-20 mm internal diameter) test graft using 3/0 monofilament polypropylene suture for proximal anastomosis and 4/0 suture for distal. Inferior mesenteric artery was re-implantated into the prosthesis using Carrel's patch technique 8 in selected cases upon indication. CoA repair was performed through left postero-lateral thoracotomy. Excision of coarct segment and interposition graft placement using 14-16 mm ID test graft was done in one patient while Fig. 3 . Replacement of segment of descending thoracic aorta in pig with the test graft using standard protocol via left postero-lateral thoracotomy (A). Gross healing characterstics of test vascular graft at explant post-6 month in vivo in pig in 8, 4 and 12 cm lengths respectively (B, C, D). Neointima was found to be smooth in short replacements while it was less regular and even, nonetheless thrombusfree, in long grafts. Parameters were carefully noted regarding handling qualities of prosthesis and procedure related complications or mortality. Postoperative status regarding distal pulses and ABI were documented (Table III) . Patients were followed up for a maximum period of five years using clinical and imaging documentation of graft patency and integrity.
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Long-term follow up till date:
Patients recruited in the clinical trials that involved implantation of the test graft at the institute as well as the control group were followed up by clinical examination and duplex ultrasound on yearly basis. CT scan/magnetic resonance angiography (MRA) were performed yearly for first two years and thereafter once in 2-3 years of follow up.
Parameters evaluated were (i) Dilatation and elongation -No progressive dilatation > 15 per cent/ that of control grafts (as measured in systole). (ii)
Structural stability -should be non-biodegradable. 
Results
In vitro testing:
The results of the study did not show any significant irritation or systemic toxicity with physiological saline and cotton seed oil extracts of the material. The percentage of haemolysis induced by the material and extract was under acceptable range. Results of the histopathological evaluation suggested that the material did not produce any histopathological changes. Hence the toxicity study concluded that the material was non toxic, non irritant, non haemolytic and biocompatible.
Pre-clinical animal testing
(i) Immediate -All animals, except one (15 th ), were extubated at the end of procedure and walked back to their cage 6-8 h thereafter. The 15 th animal which underwent interposition graft using cardiopulmonary bypass to support circulation succumbed to air embolism at the end of an otherwise satisfactory procedure. Another animal died on 2 nd post-operative day following hyperpyrexia of 104°F and at autopsy graft was noted to be patent. The third animal developed delayed paraplegia 24 h after operation that involved 45 min of aortic cross-clamping, had to be sacrificed and at autopsy the prosthetic graft was found to be patent and void of any thrombus. Hence the remaining 12 animals were available for explantation to study the healing characteristics.
(ii) Explantation data -Explantation was performed at three and six months after graft implantation under general anaesthesia. Animals weighed 55 and 65 kg, respectively; 1 mg/kg heparin was administered to avoid misinterpretation of pre-and post-mortem thrombus.
Gross examination showed that the grafts were well incorporated in a 1-4 mm thick perigraft capsule. No pseudoaneurysm was noted in either of the groups. Cut surface showed that suture lines were tidy and clean with no evidence of thrombus formation. The body of the prosthesis was glistening white with well organized neo-intima. However, neoimtima inside long grafts appeared irregular and uneven but well organized in contradistinction to smooth glistening thin lining in short replacements (Fig. 3B-D) Histologically, the inner lining was thin and measured 0.6-1.0 mm, and showed uniform regular neointima of fibro-collagenous tissue, a few islands of calcification along with cellular infiltration of lymphocytes and a few foreign body giant cells (Fig. 4) .
Phase I clinical trial:
First patient following repair of AAA was discharged from hospital on 10 th day. At discharge, her blood pressure was controlled with 50 mg Atenolol (beta-aderenergic blocker) and her ankle brachial index was 1.1. She was maintained on aspirin and iron supplementations as well. CT scan prior to discharge showed patent graft, intact suture lines, smooth luminal outline and patent inferior mesenteric artery. She was evaluated in person five years after surgery. In 2013, a telephonic interview confirmed her wellbeing with no complaints regarding abdomen.
All patients survived major surgical procedure and made satisfactory early recovery except one patient (4 th ) who underwent surgical repair for complex postsubclavian coarctation of aorta with large heavily calcified post-coarct aneurysm, who developed Minor sequelae in others included prolonged paralytic ileus in two and respiratory infection in one (Table  II) . All patients were discharged from hospital on or before 10 th postoperative day except the patient who developed paraplegia (20 days). All patients underwent Duplex ultrasound and CT scan before discharge from hospital which showed satisfactory repair, patent graft and smooth regular luminal surface of prosthesis.
Complete follow up was available for all 10 patients at three, six months, one year and yearly thereafter. All patients were in good health and active except the 4 th patient who did not recover from paraplegia inspite of aggressive physiotherapy. ABI at follow up ranged from 0.85 to 1.1. CT/conventional aortogram was done at discharge and on yearly follow up (Fig. 5) . The inner diameter of the graft as measured in CT/aortogram was 0.5-0.7 mm less than the internal diameter of the appropriate graft size. This feature matched the control group of DuPont Dacron grafts used in similar locations.
All patients who received the test implant survived the procedures and recovered well except the patient who developed paraplegia; however, digital substraction angiography (DSA) at one year and CT aortogram at five years showed intact repair with patent graft. Host-graft interaction was reflected at three sites namely, aorta to graft interphase, outside the graft and its inner luminal surface. No untoward sequelae of excessive intimal hyperplasia or pseudoaneurysm formation were noted in and around the proximal and distal suture lines in these patients. The incorporation of the graft in the form of perigraft capsule appeared satisfactory. The luminal side of the grafts were clean and regular with no evidence of thrombus formation inside the test or control grafts.
Phase II clinical trial: Prosthesis was found to be surgeon friendly, with excellent suturing and suture retention qualities. All centres reported good graft handling qualities with pliability, lack of fraying, ease of pre-clotting and suturing and absence of excessive weeping following implantation similar to control Dacron grafts. Patients were electively ventilated for 4 to 24 h with mean of 8 h as dictated by their clinical condition. All 22 patients at 4 centres of study made satisfactory early recovery from appropriate procedures. Two patients (both TAAA) developed transient renal dysfunction (increase in serum creatinine >1 mg/dl higher than pre-operative level) eventually normalising at discharge. Follow up visits were planned at three and six months, one year and yearly thereafter. Apart from regular clinical assessment, duplex scan evaluation was performed in patients with graft implantation in abdomen. Check MR/CT angiogram was performed on follow up showed preserved patency with no evidence of graft-related complications (Fig. 6) .
One patient succumbed to stroke 18 months after aorto-femoral graft procedure; and another to road traffic accident leading to irreversible brain damage three years after AAA repair. Post-operative ABI at 1-4 years were 0.9 or more in 15, 0.8 in 4, and 0.7 in 3 (Table III) . Long-term follow up till date: Follow up was complete in eight patients at >10 yr after implantation of test vascular prosthesis in phase I trial and >5 yr in 14 patients in phase II trial. Three patients who were around 70 yr of age in 1998-1999 died of old age and cardiac events beyond five years after the operation. Present evaluation has confirmed excellent clinical status of the survivors and satisfactory graft function with no incidence of pseudoaneurysm, aneurysm, infection, thrombosis, dilatation or any other untoward sequelae with reference to implanted vascular prosthesis (Fig.  7) 9 , except one 32 yr old patient with thoraco-abdominal aortic aneurysm due to Takayasu's disease was noted to have pseudoaneurysm at distal aortic anastomosis five years following surgery requiring endovascular aortic stent grafting. Two patients were lost to follow up beyond one year.
Discussion
This study reports indigenously fabricated polyester graft developed and extensively tested in vitro, than tested in vivo using large animal, prior to clinical study by implantation in patients. Each batch of grafts was put through physical (yarn count, twist and tensile strength), chemical (infra-red spectroscopy and thermal analysis) and toxicity (intracutaneous injection, haemolysin and intramuscular implantation in mice) tests with satisfactory results in accordance with standards laid down by Association for the Advancement of Medical Instrumentation (AAMI) and American National Standards Institute (ANSI) graft research as implantation data of three months in growing pigs in terms of healing patterns and characteristics were noted to be equivalent to three years in man.
Pore size of prosthesis is essential for ingrowth of fibroblasts and capillary buds from peri-graft tissue to form and stabilize neointima in the graft body. However, larger pore size results in bleeding through its interstices. Hence the optimal pore size is a trade off that minimizes blood loss through interstices while permitting ingrowth of fibroblasts and capillaries to augment neointimal healing 11 . The woven test graft porosity was 200 ± 50 ml/cm 2 /min of normal saline at 120 mmHg. No bleeding problem was encountered through the prosthesis after blood pre-clotting when partial heparinisation (1 mg/kg) was employed. For the experiment performed under cardio-pulmonary bypass, plasma pre-clotted and autoclaved test graft appeared impervious to blood during implantation and thereafter.
Subsequent to general concerns of survival, toxicity, allergy and rejection, in vivo animal experiments primarily focused on study of explanted vascular grafts at varying intervals after implantation. Study of explanted graft, in turn, was further characterized by:
(i) Structural integrity of the prosthesis and freedom from dilatation/pseudoaneurysm formation.
(ii) Patency in general, indicating the functional ability of graft in conducting blood for distal perfusion.
(iii) Perigraft capsule formation signifying the incorporation of foreign device into the host tissue.
(iv) Neointima formation, which constitutes the most critical determinant of optimal functioning of prosthetic graft in living body, the quality of which is inversely proportional to thrombogenicity. Major sources of endothelialisation are as follows; across suture lines by direct growth from either ends, by deposition of fibroblasts and wandering endothelial precursor cells (EPCs) in the bloodstream onto the platelet-fibrin layer on the inner side, or by transmural ingrowth of fibroblasts and capillary beds from perigraft tissue entering through the pores of woven/ knitted fabric 12 
.
Structural integrity was well preserved and the anastomotic suture lines appeared covered with a transparent fibrin layer separating the flowing blood in the prosthesis. All grafts were incorporated into the perigraft capsule and developed a compact layer of neointima, with a thickness from 0.1-1.0 mm depending upon the diameter of graft, size of parent vessel, distal run-off and, to a certain extent, the surgical technique. In all short segment grafts, neointima appeared very thin, pink, shiny and intimately adherent as expected as endothelialisation is easily possible from both ends of native aorta. However, in long grafts, neointima was thicker (1-1.2 mm), whitish, slightly irregular but still clean and free from thrombus.
In human studies, permanent implants like vascular prostheses must provide optimal safety for the recipient patient along with efficacy and performance for a long duration with uninterrupted functional integrity (Table IV) 2 . Reporting standards laid down by Ad-hoc committee of the Joint Council of Society of Vascular Surgery and International Society of Cardiovascular Surgery, North American Chapter, mandates a preliminary assessment at two years and final report at five years before multicentric trials can be resorted to 2 . Safety, efficacy and performance standards of the graft were found to be excellent in this study, even beyond six years and in some patients continuing beyond 14 years. Similarly, patients in multicentric trial were followed up for duration of at least five years. No device-related complications occurred in any of the patients in clinical trials.
All patients had optimal graft performance status on follow up with continued patency and absence of thrombus formation, pseudoaneurysm formation, loss of tensile strength, progressive dilatation or infection. There was only one incidence of anastomotic pseudoaneurysm in the entire series which involved a 32 yr old patient who developed distal anastomotic pseudoaneurysm four years after an intact repair of thoraco-abdominal aortic aneurysm, who also had a previous history of carotid pseudoaneurysm following carotid bypass. The occurance of such anastomotic pseudoaneurysms is not uncommon in Takayasu's disease 13 especially in the setting of long-term steroid usage. This follow up study over a protracted period of 6-14 years has proven safety to patients. The results compared favourably with published data on long-term biostability of polyester vascular prosthesis which reported 95 per cent 10 yr patency rates and structural failure rate of 0.2-3.0 per cent [14] [15] [16] .
In conclusion, indigenously designed, developed and thereafter comprehensively performed clinical trials have provided robust data regarding safety and efficacy of indigenously developed vascular prosthesis during an extended study period of over a decade. In a total of 32 patients, with diverse clinical conditions and ages thus studied in the clinical trials encompassing both single-centre and multicentric phases, no complications or adverse events occurred. The technique of coating the prosthesis to render it impervious to blood at implantation 17 , thus obviating the need for preclotting prior to implantation, was introduced to the Chitra vascular graft as well. Laboratory testing and in vivo experiments in 30 pig models were completed and the coated graft will undergo clinical trial to prove its safety and efficacy before making it available on shelf.
